Replies to post #152581 on Biotech Values

[biomaven0]

Avastin has a consistent pattern of PFS improvement with dubious OS results. MIght correspond to selecting for tumor stem cells.

In this case, however, there is likely a clear clinical benefit in shrinking/stabilizing brain tumors even if it doesn't improve OS.

Peter

[caravon]

"Temodar+radiation +/- Avastin; the HR for PFS was 0.64 (p<0.0001).

Although the OS data are still maturing, they almost certainly won’t be statsig; at the most recent checkpoint, the HR for OS was 0.89 (p=0.21)."

Early treatments benefits are in but then something did not go the Right Way. May be the combo is missing an additional treatment component?